Leukocytoclastic vasculitis due to thalidomide in multiple myeloma

Japanese Journal of Clinical Oncology

Volumn 37, Issue 9, 2007, Pages 704-707

  Yildirim, Naciye Demirel ^a,c   Ayer, Mesut ^a   Küçükkaya, Reyhan Diz ^a   Alpay, Nilüfer ^a   Mete, Özgür ^b   Yenerel, Mustafa Nuri ^a   Yavuz, Akif Selim ^a   Nalçaci, Meliha ^a  

^a Division of Hematology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Barbaros MahFidan Sok ^*  (Turkey)

Author keywords

Leukocytoclastic vasculitis; Multiple myeloma; Thalidomide; Zoledronic acid

Indexed keywords

LACTATE DEHYDROGENASE; MELPHALAN; METHYLPREDNISOLONE; PREDNISOLONE; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; ANAPHYLACTOID PURPURA; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; BONE PAIN; BONE RADIOGRAPHY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CASE REPORT; COMPRESSION FRACTURE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAVASATION; FOLLOW UP; HEMATURIA; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LEUKOCYTOCLASTIC VASCULITIS; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPHIL CHEMOTAXIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PARAKERATOSIS; PROTEINURIA; PUNCH BIOPSY; PURPURIC RASH; URINALYSIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE; VASCULITIS, HYPERSENSITIVITY;

EID: 35448982011     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym092     Document Type: Article

References (13)

1. Hattori Y, Iguchi T. Thalidomide for the treatment of multiple myeloma. Congenit Anom (Kyoto) 2004;44(3):125-36.
2. Cem Ar M, Soysal T, Hatemi G, Salihoglu A, Yazici H, Ulku B. Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Ann Hematol 2005;84(9):609-13.
3. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1): 210-16.
4. Witzens M, Moehler T, Neben K, Fruehauf S, Hartschuh W, Ho AD, et al. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Ann Hematol 2004;83(7):467-70.
5. Rees MM, Rodgers GM. Cutaneous leukocytoclastic vasculitis. In:GReer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B editors. Wintrobe's Clinical Hematology. Philadelphia, PA: Lippincott Williams & Wilkins 2004; 1579.
6. Bayer-Garnet IB, Smoller BR. Leukocytoclastic (small vessel) vasculitis in multiple myeloma. Clin Exp Dermatol. 2003;28(5):521-4.
7. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003; 40(4 Suppl 4):3-7.
8. Rajkumar SV, Dispensieri A, Fonseca R, Lacy MQ, Geyer.S, Lust JA, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001;15(8):1274-6.
9. Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363(9412): 875-87.
10. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 1999;341(21):1565-71. [Erratum in New Engl J Med 2000;342(5):364.]
11. Singhal S, Mehta J. Novel therapies in multiple myeloma. Int J Hematol 2003; 77(3):226-31.
12. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132(5):584-93.
13. Milehskin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory, multiple myeloma: Adverse prognostic impact of advanced age. Blood 2003; 102(1):69-77.